The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or reversible obstructive airway disease. “Metered dose inhalers like these are known as complex generics, which are traditionally harder to copy because of their complex formulation or mode of delivery,” said FDA Commissioner Stephen Hahn, M.D. “As a result, too many complex drugs lack generic competition even after patents and exclusivities no longer block generic approval. Supporting development and approval of generic copies of these complex medicines so that these products can get to patients has been a major focus of our efforts to improve competition and access and to lower drug prices.”

Related News Articles

Headline
The AHA May 21 voiced support to Senate and House sponsors of the Improving Seniors’ Timely Access to Care Act, legislation that would reduce the variation in…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Perspective
Public
Three key House committees — Energy and Commerce, Ways and Means, and Agriculture — after long debates and discussions this week advanced their portions of a…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…
Perspective
Public
After a week’s delay to try to build consensus among Republicans — due in large part to concerns we have been raising about Medicaid cuts —  the House…